ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Lung Cancer trials near Durham, NC, USA:

Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer (FIRSTLungL301)

The purpose of this study is to determine whether availability of DNA Evaluation of Fragments for Early Interception (DELFI) Lung Cancer...

Enrolling
Lung Cancer
Other: Continuing Medical Education for Lung Cancer
Diagnostic Test: Ability to order FirstLook™
Delfi Diagnostics

Durham, North Carolina, United States

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Chapel Hill, North Carolina, United States and 43 other locations

The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by inves...

Active, not recruiting
Relapsed/Refractory Small Cell Lung Cancer
Drug: Tarlatamab

Phase 2

Amgen
Amgen

Durham, North Carolina, United States and 79 other locations

study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung...

Not yet enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Lurbinectedin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Durham, North Carolina, United States of America and 198 other locations

in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who ha...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

Phase 2

Pfizer
Pfizer

Durham, North Carolina, United States and 156 other locations

results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platin...

Enrolling
Extensive-stage Small-cell Lung Cancer
Drug: Ifinatamab Deruxtecan (I-DXd)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Durham, North Carolina, United States and 100 other locations

overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: Nab-Paclitaxel
Drug: Cisplatin

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Durham, North Carolina, United States and 126 other locations

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...

Active, not recruiting
Small Cell Lung Cancer
Drug: Durvalumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Chapel Hill, North Carolina, United States and 181 other locations

and anti-PD1 therapy for subjects with refractory non-small cell lung cancer.The purpose of this study is to:1. Test the safety and...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: C-TIL051

Phase 1

AbelZeta

Raleigh, North Carolina, United States

survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer...

Enrolling
Extensive-stage Small Cell Lung Cancer
Biological: BMS-986012
Biological: Nivolumab

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Durham, North Carolina, United States and 42 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems